Entresto Label: Strong Efficacy, Complex Dosing
Executive Summary
PARADIGM-HF study shows 20% reduced risk of CV death and heart failure hospitalization compared to ACE inhibitor enalapril.
You may also be interested in...
Novartis’ Entresto Labeling Expansion Bid Heads To US FDA Panel
Cardiovascular and Renal Drugs Advisory Committee will consider whether exploratory analyses from the PARAGON-HF trial, which narrowly missed its primary endpoint, plus demonstrated efficacy in an adjacent indication, support a new claim for heart failure patients with preserved ejection fraction.
Novartis's Entresto Voyage: Hindsight Is 20/20
What caused Novartis's innovative heart failure drug to falter, missing sales targets by $30m in 2016, and how is it expected to bounce back in 2017? Scrip explores Entresto's journey and what this experience shows about the changing face of pharma's customers.
US FDA Commissioner Califf Takes On Misinformation, Starting With ‘Rumor Control’
Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.